Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
06-25 | Biotech Firm Clario Eyes IPO Early in 2025 | MT |
06-25 | Sector Update: Financial Stocks Fall Late Afternoon | MT |
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Ratings chart - Surperformance
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 571B | - | ||
+16.96% | 313B | C+ | ||
+19.90% | 258B | C+ | ||
+24.30% | 188B | B- | ||
+29.19% | 171B | B- | ||
+8.10% | 161B | C+ | ||
+0.12% | 152B | B- | ||
+8.39% | 150B | B- | ||
+13.48% | 141B | C+ | ||
+23.29% | 118B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JPM Stock
- JPM Stock
- Ratings JP Morgan Chase & Company